Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 5, 2003. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs), rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to employee benefit plans.
Material Changes
- Employee Share Option Plan: On September 3, 2003, the GlaxoSmithKline Employee Trust transferred 7,100 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan: On September 4, 2003, the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 19,099,918 to 19,007,554. This movement occurred at an average price of $40.21.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that Directors Dr. J-P Garnier and Mr. J D Coombe are interested in the shares held in the GSK Trust, and Dr. J P Garnier is potentially interested in the shares held in the US Retirement Savings Plan, in the same capacity as other employees.
Key Facts for Investor Verification
- Verify the impact of the 7,100 share transfer on the total outstanding share count.
- Confirm the valuation of the US Retirement Savings Plan holdings based on the reported average price of $40.21.
- Review the full 20-F annual report for comprehensive financial performance data, as this 6-K does not contain financial statements.